Nanjing King-Friend Biochemical Pharmaceutical Bundle
Who Owns Nanjing King-Friend Biochemical Pharmaceutical Company?
Understanding the ownership of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is key to grasping its strategic path and governance. Its public listing marked a significant shift, broadening its investor base and influencing its corporate structure.
The company, established around 1998-2000, focuses on vital anticoagulants like heparin sodium. Its integrated approach spans from sourcing raw materials to selling finished goods, aiming for global reach.
As of August 15, 2025, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. has a market capitalization of approximately $2.57 billion USD, with 1.62 billion shares outstanding. In 2023, it held about a 5% share of China's pharmaceutical API market. This analysis explores how founders, institutional investors, and public shareholders have influenced its ownership over time, including its role in the Nanjing King-Friend Biochemical Pharmaceutical PESTEL Analysis.
Who Founded Nanjing King-Friend Biochemical Pharmaceutical?
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. was established around 1998-2000, with Yongqun Tang identified as a key figure, holding the roles of Legal Representative, Chairman, and General Manager. While the precise details of all founders and their initial stakes are not publicly documented, the company's early development was supported by venture capital. This included a Series A funding round in April 2011, which saw investment from firms like Vivo Capital and Matrix Partners China.
| Founding Period | Key Figure Identified | Early Funding | Notable Early Investors |
|---|---|---|---|
| Late 1990s / Early 2000s | Yongqun Tang (Legal Representative, Chairman, General Manager) | Venture Capital (Series A in April 2011) | Vivo Capital, Matrix Partners China |
Founding Era
The company's inception occurred between 1998 and 2000. This period marked the beginning of its operations in the biochemical pharmaceutical sector.
Key Leadership
Yongqun Tang is a prominent figure, serving as the Legal Representative, Chairman, and General Manager. His roles suggest significant influence and likely a founding contribution.
Venture Capital Backing
The company benefited from early venture capital support. It was described as 'formerly VC-backed' prior to later developments.
Series A Funding
In April 2011, the company raised an undisclosed amount in a Series A funding round. This capital infusion was crucial for its growth.
Early Investors
Key investors participating in the Series A round included Vivo Capital and Matrix Partners China. These firms provided early financial backing.
Founding Vision
The founding team's objective was to build a strong pharmaceutical enterprise. Their focus was on heparin-related products and expanding into global markets.
Specific details regarding the full names of all initial founders, their exact backgrounds, and the precise initial equity distribution remain undisclosed in public records. However, the company's strategic direction was clearly established from its early days, focusing on specialized pharmaceutical products and international market penetration, as detailed in its Brief History of Nanjing King-Friend Biochemical Pharmaceutical.
Early Ownership Landscape
While precise founder information is limited, Yongqun Tang's prominent leadership roles suggest a foundational involvement. The company's early reliance on venture capital indicates a structure that involved external investment from its nascent stages.
- Founding years: 1998-2000
- Key figure: Yongqun Tang
- Early funding source: Venture Capital
- Series A round: April 2011
- Major early investors: Vivo Capital, Matrix Partners China
Nanjing King-Friend Biochemical Pharmaceutical SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Nanjing King-Friend Biochemical Pharmaceutical’s Ownership Changed Over Time?
The ownership evolution of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. saw a significant shift with its public listing on the Shanghai Stock Exchange on July 19, 2017. This event, under the ticker 603707, with an offering of 63.50 million shares at 7.21 yuan per share, opened the door for broader ownership participation.
| Shareholder Category | Ownership Percentage (End of 2022) | Number of Shares (Approx.) |
|---|---|---|
| Institutional Investors | 45% | 450 million |
| Individual Shareholders | 35% | 350 million |
| Company Insiders | 15% | 150 million |
| Other Investors | 5% | 50 million |
As of August 15, 2025, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. commands a market capitalization of approximately $2.57 billion USD, with 1.62 billion shares in circulation. The company's ownership structure at the close of 2022 reflects a diversified base, with institutional investors holding 45% (450 million shares) and individual shareholders representing 35% (350 million shares). Company insiders own 15% (150 million shares), and other investors hold the remaining 5% (50 million shares). The largest single institutional stakeholder is China Securities Finance Corporation Limited, which possesses around 15% of the company's shares, totaling approximately 150 million shares. Other significant institutional shareholders include Bank of Communications Schroder Fund Management Co., Ltd., HuaAn Fund Management Co., Ltd., and China Southern Asset Management Co., Ltd., alongside various mutual funds and investment firms with a focus on the healthcare industry. This transition to a publicly traded entity, coupled with the substantial involvement of major institutional investors, has played a crucial role in shaping the company's governance and aligning its strategic direction towards sustained expansion within the pharmaceutical and biotechnology sectors. Understanding the Revenue Streams & Business Model of Nanjing King-Friend Biochemical Pharmaceutical provides further context to these ownership dynamics.
Key Stakeholders in Nanjing King-Friend Ownership
The ownership of Nanjing King-Friend Biochemical Pharmaceutical Company is spread across various groups, reflecting its status as a publicly traded entity.
- Institutional Investors collectively hold the largest portion of shares.
- Individual investors represent a significant segment of the shareholder base.
- Company insiders maintain a notable stake, influencing internal strategy.
- China Securities Finance Corporation Limited is identified as the primary institutional investor.
Nanjing King-Friend Biochemical Pharmaceutical PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Nanjing King-Friend Biochemical Pharmaceutical’s Board?
The governance of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is structured around its Board of Directors, tasked with overseeing the company's strategic direction and operations. While specific board compositions can evolve, the aim is to maintain a balance between the interests of various stakeholders, including institutional investors and company management, ensuring robust oversight of the King-Friend Pharmaceutical company structure.
| Role | Name | Key Responsibilities/Affiliations (as of earlier records) |
|---|---|---|
| Chairman, Director, General Manager | Yongqun Tang | Overall leadership and management |
| Director | Tao Wang | Board representation |
| Director, Audit Committee Member | Juhua Xie | Financial oversight |
| Director, Board Secretary, Deputy General Manager | Xiwei Huang | Corporate governance and management support |
| Independent Director | Guoqing Cui | Committee chair (e.g., Audit, Nomination) |
| Independent Director | Yi Jin | Committee chair (e.g., Audit, Nomination) |
The voting power within Nanjing King-Friend Biochemical Pharmaceutical Company is generally understood to operate on a one-share-one-vote principle, a common structure in publicly traded entities unless otherwise specified. There is no public information indicating the existence of dual-class shares or other mechanisms that would grant disproportionate voting rights to specific shareholders, which is crucial for understanding Nanjing King-Friend ownership. The influence of key leadership figures, such as the Chairman and General Manager, Yongqun Tang, in combined roles, suggests a centralized decision-making authority, a factor to consider when analyzing the King-Friend Pharmaceutical owner dynamics.
Understanding Shareholder Influence
The structure of voting power is a critical element in determining who owns King-Friend Biochemical and how decisions are made. Understanding the distribution of shares and voting rights provides insight into the controlling interest of the company.
- One-share-one-vote is the presumed standard.
- No public disclosure of special voting rights or dual-class shares.
- Chairman's combined role indicates significant leadership influence.
- Analysis of Nanjing King-Friend stock ownership is key to understanding control.
- The Marketing Strategy of Nanjing King-Friend Biochemical Pharmaceutical is influenced by its ownership and governance.
Nanjing King-Friend Biochemical Pharmaceutical Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Nanjing King-Friend Biochemical Pharmaceutical’s Ownership Landscape?
Over the past three to five years, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. has navigated significant financial shifts and strategic ownership adjustments. The company's financial performance has seen a notable turnaround, with substantial revenue growth and a significant increase in net income attributable to shareholders.
| Financial Period | Revenue (CNY) | Net Income Attributable to Shareholders (CNY) | Year-on-Year Change (Net Income) |
|---|---|---|---|
| 2024 | 3,924,000,000 | 826,000,000 | 536.09% |
| Q1 2025 | N/A | 84,710,000 | -52.19% |
| H1 2024 | 2,139,450,000 | 405,020,000 | N/A |
The company has actively engaged in share repurchases, demonstrating a commitment to shareholder value. As of July 31, 2025, Nanjing King-Friend had repurchased 880,000 shares, representing 0.05% of its total share capital, for a total of RMB 10,220,700. This move aligns with a broader strategy of international expansion, exemplified by the acquisition of a majority stake in US injectables specialist Meitheal Pharmaceuticals in 2019. Industry analysis suggests a continued emphasis on innovation and global market penetration, with foreign revenues comprising a significant 76.75% of total revenue in 2024. Public statements indicate a forward-looking approach, focusing on monitoring policy trends and accelerating the development of its overseas formulation commercialization platform.
Share Buyback Initiative
Nanjing King-Friend announced an equity buyback plan valued at CNY 40 million. As of late July 2025, the company had repurchased 880,000 shares, amounting to 0.05% of its total share capital.
International Market Expansion
The company strategically expanded its global presence by acquiring a majority stake in Meitheal Pharmaceuticals in 2019. Foreign revenues constituted 76.75% of total revenue in 2024, highlighting a strong international focus.
Financial Performance Trends
The company reported a substantial revenue of 3.924 billion yuan in 2024, with a net income of 0.826 billion yuan, a significant increase from prior periods. However, Q1 2025 saw a decrease in net income due to declining gross margins on key products.
Strategic Outlook and R&D Investment
There is a continued emphasis on innovation, with a significant allocation of revenue towards research and development. The company plans to monitor policy trends and enhance its overseas formulation commercialization platform.
Nanjing King-Friend Biochemical Pharmaceutical Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Nanjing King-Friend Biochemical Pharmaceutical Company?
- What is Competitive Landscape of Nanjing King-Friend Biochemical Pharmaceutical Company?
- What is Growth Strategy and Future Prospects of Nanjing King-Friend Biochemical Pharmaceutical Company?
- How Does Nanjing King-Friend Biochemical Pharmaceutical Company Work?
- What is Sales and Marketing Strategy of Nanjing King-Friend Biochemical Pharmaceutical Company?
- What are Mission Vision & Core Values of Nanjing King-Friend Biochemical Pharmaceutical Company?
- What is Customer Demographics and Target Market of Nanjing King-Friend Biochemical Pharmaceutical Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.